Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart versus IVIg in adults with multifocal motor neuropathy
CTR20252964Phase 3Active
- Sponsor
- 不适用/ 百时益医药研发（北京）有限公司
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of empasiprubart, immune globulin in multifocal motor neuropathy (MMN), sponsored by 不适用/ 百时益医药研发（北京）有限公司. Started Oct 2025; status: active.
02
Drugs
empasiprubartimmune globulin
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on CTR20252964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252964.